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Delayed-type  hypersensitivity  (DTH)  appears  in  mice  immunized  with 
sheep  red  blood cells  (SRBC)  if  the  dose of antigen  is  matched  to the  route 
of  immunization  (1).  The  optimum  intravenous  dose  for  sensitizing  CD-1 
mice  is  10  s  SRBC.  As  the  dose  is  raised  above  this  optimum,  DTH  dimin- 
ishes, disappearing  completely beyond  l0  s.  No subsequent  dose of SRBC, by 
any route,  will induce DTH  once T  cells have been blocked by previous im- 
munization.  Blocking is due  to a  product  of the  interaction  between  antigen 
and antibody (presumably an immune complex)  (2). The formation of specific 
antibody can  be  temporarily  prevented  by cyclophosphamide  (CY)  (3),  thus 
liberating  the  T-cell  response  from  feedback  inhibition  and  allowing  DTH 
to  reach  abnormal  levels  in  response  to doses  of antigen  that  would  abolish 
DTH completely in untreated mice (4). 
A  systemic infection with  BCG also amplifies  the T-cell response to SRBC. 
It does  so  by interfering  with  the  blocking mechanism  that  normally  limits 
the T-cell response  (5). The effects of CY  and BCG, being  additive,  combine 
to produce spectacular  levels of DTH  which  may persist  for 6  mos or more? 
Augmentation  of  the  T-cell  response  to  a  first  encounter  with  antigen  may 
be  less  important,  however,  than  the  problem  of  reestablishing  cell-medi- 
ated  immunity  after  T  cells  have  become  blocked  by  a  humoral  response. 
We  need  measures,  for  example,  that  will  rescue  T  cells  from  subjugation 
by products  of the  humoral  response  in  tumor-bearing  (6)  or chronically  in- 
fected (7) subjects. 
Materials and Methods 
All materials and methods have been described (1, 2, 4, 5, 8, 9). 
Animals.--Specific pathogen-free mice of the CD-1 strain  (Charles River Breeding Labo- 
ratories, Wilmington, Mass.) were used at 3-6 wk of age. 
Mycobaclerium Boris BCG.--The  Pasteur  strain  of BCG  (Trudeau  Mycobacterial  Col- 
lection no.  1011) was cultivated  in  Middlebrook's  7H9 medium  (Difco Laboratories,  De- 
troit,  Mich.) and frozen while in log-phase growth. It was preserved at --70°C in vials con- 
taining 4 X  10  s viable BCG/ml. 
Cydophosphamide.--Cytoxan (CY) was donated  by Mead  Johnson and  Co., Evansville, 
Ind. It was dissolved in sterile saline (20 mg/ml)  and administered intravenously  as a single 
dose (200 mg/kg). 
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Delayed-Type Hypersensitivity.--DTH was measured as the increase in footpad thickness 
24 h after inoculation of an eliciting dose of 10  s SRBC (9). 
RESULTS 
DTH was  blocked on day 0  by a  massive intravenous injection of  109  SRBC. 
Half  the  immunized mice  were  given  l0  T viable BCG  Pasteur  intravenously on 
day  14. Half of  these and an equal number of uninfected mice were given CY on 
day 28.  On day  30,  mice of all groups  (untreated, BCG,  CY,  BCG  W C¥)  were 
subdivided and injected intravenously with a  second antigenic stimulus of varying 
intensity (105-10 s SRBC).  DTH was measured 6 days later in the right hind foot- 
pad. 
Fig.  1  a  shows  that previously immunized mice did  not develop DTH  in 
response to any of the doses of antigen used for the secondary stimulus. But 
mice given either CY or BCG developed some degree of DTH. Those given both 
BCG and CY, however, responded vigorously; behaving, in fact, as if they had 
never previously encountered SRBC  (5).  The hemagglutinating titer  at  the 
time of attempted rescue of T-cell activity was 1 : 1024. 
A second attempt to restore T-cell activity was begun 60 days after the pri- 
mary  (suppressing)  dose  of  109  SRBC.  The  antibody titer  was  still  1:512. 
Fig. 1 b shows that the response to reimmunization with 108 SRBC  produced 
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FIG. 1.  (a) Animals which have previously been immunized with a T-cell-blocking dose 
of SRBC (109) will not subsequently respond with the development of DTH to any dose 
of SRBC in the range  105-10  s (*--*). Treatment with CY (&--A) 2 days before, or in- 
fection with  BCG  (e--e)  12  days before antigenic stimulation,  allowed some degree of 
T-cell activity to emerge. Treatment with  both agents  (ll---i), however, restored  the re- 
sponse almost to normal (5). Means of five -4- SEM. (b) The rate of development, magni- 
tude, and duration of the DTH provoked by the highest (10  s) dose of SRBC in mice belong- 
ing to the four groups of mice described in (a) above. Means of five :t: SEM. MACKANESS  AND  LAGRANGE  BRIEF  DEFINITIVE  REPORT  867 
peak levels of DTH that were not much less than those achieved by animals 
responding for the first time under identical conditions of treatment with BCG 
and CY to the same dose of SRBC (5). 
The Suppression of T-Cell Activity During Prolonged Exposure to Antigen.-- 
Beginning with  an  initial dose  of  50  SRBC, mice  were  exposed  to  gradually  in- 
creasing amounts of antigen by successive  twofold  increments in the daily dose of 
SRBC. The first 10 injections were given intravenously, the rest intraperitoneally. 
At S-day intervals, groups of five mice were tested for DTH, and then were bled to 
determine the prevailing levels of hemagglutinating  antibody. 
Fig. 2 a  shows that  the high point of  T-cell reactivity was  achieved on  day 
10,  when  the  cumulative dose  of  SRBC  had  reached  about  105. Antibodies 
were still not present at this time, but the level of DTH was much less than 
would have been reached within 4 days of injecting a single pulse of 105 SRBC 
(1). Antibody appeared in the serum after day 10 and DTH began to decline 
Fro. 2. (a) DTH was measured at 5-day intervals (O--O) in groups of mice drawn from 
a much larger pool of animals which received SRBC in twofold increments on each succes- 
sive day. The cumulative dose of SRBC is represented by the interrupted  line. The total 
and mercaptoethanol-resistant  hemagglutinin titers  (log2) at each time point are recorded 
beside the mean (:t=SEM) footpad reactions elicited in groups of five mice. (b) Mice which 
had become anergic after receiving a total dose of 10  9 SRBC were used to test the capacity 
of BCG and CY to restore T-cell responsiveness. The experimental design is described in 
the text. Tests for DTH were performed 6 days after restimulation with  l0  s SR_BC. Mice 
not given this resuscitating  intravenous  injection of antigen are  represented by the black 
columns. Means of five -4- SEM. The total/2 ME-resistant  antibody titers  for the  pooled 
serum from each group of  mice (above each  column) show that  the  secondary antibody 
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until  it had disappeared completely by day 25  when  the cumulative dose of 
SRBC had reached 10  °. 
Restoration  of  T-Cell  Activity  to  Anergic  Mice.--As  might  happen  during 
growth of a tumor or in the course of an infection, the mice exposed to a mount- 
ing  concentration  of  antigen  passed  through  a  hypersensitive  phase  before 
becoming  completely  anergic.  The  untested  mice  remaining  in  the  experi- 
ment were therefore good  subjects  for an attempted rescue of T-cell activity. 
After DTH had disappeared on day 25, antigen injections  were stopped and  the 
mice were rested  for 5  days before commencing  the  rescue  operation.  On  day 30 
some of the suppressed mice were injected intravenously with  107 BCG; and  after 
another 20 days half of these,  and an equal number of uninfected mice, were treated 
with  CY.  2  days later,  a  secondary immunizing stimulus  of  108  SRBC  was given 
intravenously to all mice except for those  in  two additional groups: one  untreated 
and the other given both BCG and  CY. These were deliberately not given the re- 
suscitating  antigenic  stimulus  in  order  to  determine  whether  DTH would  return 
spontaneously, with or without the help of BCG and CY. 
Fig. 2 b shows that mice which were made anergic by a  continuously  increas- 
ing  exposure  to  SRBC  were  still  anergic  when  tested  25  days  after  antigen 
injections  had  ceased.  Moreover,  they  did  not  develop DTH  in  response  to 
a  resuscitating dose of antigen  (Fig.  2 b, untreated).  Mice given CY  2  days, 
or BCG 20 days, before reimmunization developed some degree of DTH; while 
those  treated  with  both  BCG  and  CY  became  intensely  hypersensitive.  It 
will be noted,  however, that DTH did not appear spontaneously.  It required 
further specific antigenic  challenge. 
DISCUSSION 
The present  experiments have shown  that  cell-mediated immunity  can  be 
reestablished  in  animals  which  have  already  responded  with  antibody  pro- 
duction  and  are  apparently  refractory  to  the  further  induction  of  DTH. 
Refractoriness  could  be  lifted  partially  by  cyclophosphamide  or  BCG;  but 
together these agents freed the T-cell response completely (Fig.  1). It was even 
possible to restore T-cell activity to animals which had been  kept under con- 
tinuous antigenic stimulation for almost 4 wk (Fig. 2). 
The  artificial  conditions  provided  by  these  experimental  models  resemble 
two  important  clinical  situations.  The  repeated  injection  of  gradually  in- 
creasing  numbers  of  SRBC  serves  to  simulate  conditions  in  tumor-bearing 
animals and in some infections in which exposure to antigen begins insidiously 
but becomes intense.  The findings with  this model  (Fig.  2)  make two poten- 
tially significant points:  that  the ultimate level of DTH  reached  was low in 
animals exposed to a  gradually increasing amount of antigen;  and  that DTH 
does  not  return  spontaneously,  even  under  the  influence  of  BCG  and  CY. 
For some reason,  the slowly mounting stimulus did not permit full expression MACKANESS  AND  LAGRANGE  BRIEF  DEFINITIVE  REPORT  869 
of T-cell activity before the inhibitory mechanism  that  blocks cell-mediated 
immunity  (2)  began  to assert itself. Had mice been injected with  10  5 SRBC 
intravenously or 10  7 SRBC subcutaneously, they would have achieved much 
higher levels of DTH (5).This shows that the cell-mediated attack on a source 
of antigen,  whether it be a  tumor or a slowly enlarging population  of micro- 
organisms  (as  in  leprosy),  may  be  interrupted  prematurely if  the  antigenic 
stimulus develops too slowly. This has obvious significance in relation to the 
concept of "sneak-through" in tumor immunology (10). 
The same experiment showed that T-cell activity did not return spontane- 
ously, even to BCG- and CY-treated animals. To restore T-cell activity, a  new 
antigenic  stimulus  had  to  be  applied,  but  the  response obtained  was  essen- 
tially  undiminished compared with  that  of previously unimmunized  animals 
(5).  Clearly the refractory animal suffers no defect in immunocompetence,  it 
is merely subject to a very efficient regulatory mechanism that precludes  the 
induction of cell-mediated immunity. 
The presumed  basis  for these  restorative effects of BCG  and  CY  are  the 
capacity of cyclophosphamide to interfere with feedback inhibition of T  cells 
by its  influence on  antibody formation  (4);  and  the  ability  of BCG,  acting 
perhaps to clear the circulation of immune complexes, to permit the  immune 
response a  longer period of evolution in  the  relative absence of feedback  in- 
hibition (5). The results show clearly that massive amounts of antigen do  not 
rob an animal of competent T  cells but merely prevent the emergence of cell- 
mediated immunity by premature inhibition.  BCG, however, has other  pos- 
sible modes of action  (5,  9), including one that postulates  the production of 
an "unblocking" antibody (11). 
Whatever the mechanism, the present observations show that it is possible 
to abolish the anergic state in an artificially suppressed animal, and encourages 
the thought  that  it may be possible to achieve similar effects in comparable 
clinical situations.  It is apparent,  however, that heroic measures,  such  as  an 
intravenous injection of living  BCG  and  a  near lethal  dose of CY,  may be 
needed. 
SUMMARY 
The T  cells which  mediate delayed-type hypersensitivity (DTH)  to sheep 
red blood cells  (SRBC)  are blocked by a  normal humoral response and can- 
not  be made  to  function  by further immunization.  They can  be  rescued  to 
some extent by treatment with immunopotentiating agents such as cyclophos- 
phamide  (CY)  which  suppresses  the  antibody  response  selectively,  or  by 
BCG  which  interferes with  the  action of serum  blocking factors.  These two 
agents together can restore cell-mediated immunity completely, but a further 
antigenic stimulus  is  needed  to  reestablish  DTH  in  mice  blocked by  a  long 
period of continuous exposure to SRBC. 870  MACKANESS  AND  LAGRANGE  BRIEF  DEFINITIVE  REPORT 
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